Overactive bladder/enuresis:

Indications for: ENABLEX

Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Adult Dosage:

Swallow whole with liquid. Initially 7.5mg once daily; may increase to 15mg once daily after 2 weeks. Moderate hepatic impairment (Child-Pugh B), concomitant potent CYP3A4 inhibitors: max 7.5mg once daily.

Children Dosage:

Not established.

ENABLEX Contraindications:

Patients with or at risk for: urinary or gastric retention, uncontrolled narrow-angle glaucoma.

ENABLEX Warnings/Precautions:

Severe hepatic impairment: not recommended. Bladder outflow obstruction. GI obstruction. Severe constipation. Ulcerative colitis. Myasthenia gravis. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider reducing dose or discontinue if occurs. High environmental temperatures. Pregnancy. Nursing mothers.

ENABLEX Classification:

Muscarinic antagonist.

ENABLEX Interactions:

Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazadone); see Adult. May potentiate CYP2D6 substrates with narrow therapeutic indexes (eg, flecainide, thioridazine, TCAs). Additive anticholinergic effects with other anticholinergics.

Adverse Reactions:

Constipation, dry mouth, headache, dyspepsia, nausea, UTI, accidental injury, flu symptoms; angioedema (discontinue if occurs), CNS effects (eg, confusion, hallucination, somnolence).


Hepatic. ~98% serum protein bound.

Drug Elimination:

Renal (60%), fecal (40%). Half-life: 13–19 hours.

Generic Drug Availability:


How Supplied:

Tabs—30, 90